TOP2A


Summary: This gene encodes a DNA topoisomerase, an enzyme that controls and alters the topologic states of DNA during transcription. This nuclear enzyme is involved in processes such as chromosome condensation, chromatid separation, and the relief of torsional stress that occurs during DNA transcription and replication. It catalyzes the transient breaking and rejoining of two strands of duplex DNA which allows the strands to pass through one another, thus altering the topology of DNA. Two forms of this enzyme exist as likely products of a gene duplication event. The gene encoding this form, alpha, is localized to chromosome 17 and the beta gene is localized to chromosome 3. The gene encoding this enzyme functions as the target for several anticancer agents and a variety of mutations in this gene have been associated with the development of drug resistance. Reduced activity of this enzyme may also play a role in ataxia-telangiectasia. [provided by RefSeq, Jul 2010].

NameOMIM IDEnsembl IDHGNC IDPHARMGKB IDMap Location
DNA topoisomerase II alphaMIM:126430Ensembl:ENSG00000131747HGNC:HGNC:11989PA35417q21.2

GO terms in TOP2A


Term TypeEvidence TypeGO Term IDGO Des.
BPIBAGO:0000712resolution of meiotic recombination intermediates
BPIBAGO:0000819sister chromatid segregation
BPIEAGO:0002244hematopoietic progenitor cell differentiation
BPIDAGO:0006265DNA topological change
BPIMPGO:0006265DNA topological change
BPIDAGO:0006266DNA ligation
BPIDAGO:0006974cellular response to DNA damage stimulus
BPIMPGO:0007059chromosome segregation
BPIBAGO:0030263apoptotic chromosome condensation
BPIDAGO:0030263apoptotic chromosome condensation
BPIEAGO:0040016embryonic cleavage
BPISSGO:0042752regulation of circadian rhythm
BPIDAGO:0043065positive regulation of apoptotic process
BPIBAGO:0044774mitotic DNA integrity checkpoint
BPIMPGO:0045070positive regulation of viral genome replication
BPIMPGO:0045870positive regulation of single stranded viral RNA replication via double stranded DNA intermediate
BPIEAGO:0045944positive regulation of transcription by RNA polymerase II
BPIEAGO:0048511rhythmic process
BPIMPGO:1905463negative regulation of DNA duplex unwinding
CCIDAGO:0000228nuclear chromosome
CCIEAGO:0000793condensed chromosome
CCIBAGO:0005634nucleus
CCIDAGO:0005634nucleus
CCIDAGO:0005654nucleoplasm
CCTASGO:0005654nucleoplasm
CCIDAGO:0005730nucleolus
CCIDAGO:0005730nucleolus
CCIDAGO:0005814centriole
CCIDAGO:0009330DNA topoisomerase complex (ATP-hydrolyzing)
CCNASGO:0019035viral integration complex
CCIDAGO:0032991protein-containing complex
CCIDAGO:1990904ribonucleoprotein complex
MFIDAGO:0000287magnesium ion binding
MFIDAGO:0003677DNA binding
MFIDAGO:0003682chromatin binding
MFHDAGO:0003723RNA binding
MFIDAGO:0003918DNA topoisomerase type II (ATP-hydrolyzing) activity
MFIMPGO:0003918DNA topoisomerase type II (ATP-hydrolyzing) activity
MFIPIGO:0005080protein kinase C binding
MFIPIGO:0005515protein binding
MFIEAGO:0005524ATP binding
MFIPIGO:0008022protein C-terminus binding
MFIDAGO:0008094DNA-dependent ATPase activity
MFIDAGO:0008144drug binding
MFIDAGO:0008301DNA binding, bending
MFIPIGO:0019899enzyme binding
MFIPIGO:0042803protein homodimerization activity
MFIPIGO:0042826histone deacetylase binding
MFIMPGO:0043130ubiquitin binding
MFIPIGO:0046982protein heterodimerization activity

Gene expression in normal tissue: TOP2A

Gene-model tissue-cancer distribution: Bubble Plot

Gene-drug pathway distribution

Pathways in TOP2A


DatabasePathway IDPathway Des.
wikipathwaysWP1858Mitotic G1-G1-S phases
wikipathwaysWP2361Gastric Cancer Network 1
wikipathwaysWP2363Gastric Cancer Network 2
wikipathwaysWP2446Retinoblastoma (RB) in Cancer
smpdbSMP00442Etoposide Action Pathway
smpdbSMP00443Teniposide Action Pathway
smpdbSMP00601Etoposide Metabolism Pathway
smpdbSMP00602Teniposide Metabolism Pathway
pharmgkbPA165292163Doxorubicin Pathway (Cancer Cell), Pharmacodynamics
pharmgkbPA2025Etoposide Pathway, Pharmacokinetics/Pharmacodynamics
piddeltanp63pathwayValidated transcriptional targets of deltaNp63 isoforms
reactomeR-HSA-1362277Transcription of E2F targets under negative control by DREAM complex
reactomeR-HSA-1538133G0 and Early G1
reactomeR-HSA-1640170Cell Cycle
reactomeR-HSA-2990846SUMOylation
reactomeR-HSA-2990846SUMOylation
reactomeR-HSA-3108232SUMO E3 ligases SUMOylate target proteins
reactomeR-HSA-3108232SUMO E3 ligases SUMOylate target proteins
reactomeR-HSA-392499Metabolism of proteins
reactomeR-HSA-392499Metabolism of proteins
reactomeR-HSA-453279Mitotic G1-G1/S phases
reactomeR-HSA-4615885SUMOylation of DNA replication proteins
reactomeR-HSA-4615885SUMOylation of DNA replication proteins
reactomeR-HSA-597592Post-translational protein modification
reactomeR-HSA-597592Post-translational protein modification
reactomeR-HSA-69278Cell Cycle, Mitotic

Gene-Drug: Aster Plot


Drug IDDrug NameModel Num.
iGMDRD427ABT7375
iGMDRD670ML 2103
iGMDRD779PRL-3 Inhibitor I1
iGMDRD781Sirolimus3
iGMDRD151CHM-14
iGMDRD433Lexibulin3
iGMDRD387CHIR-990212
iGMDRD889Compound 7d-cis4
iGMDRD420Leucascandrolide A6
iGMDRD1008SR-II-138A2
iGMDRD466Chaetocin3
iGMDRD280CYTOCHALASIN B6
iGMDRD634SCHEMBL26080411
iGMDRD446LY 21832404
iGMDRD639YK 4-2793
iGMDRD66Doxorubicin1
iGMDRD61Kinetin riboside2
iGMDRD193Fqi15
iGMDRD782DC-45-A21
iGMDRD885Compound 1103
iGMDRD870BRD636102
iGMDRD138PX 123
iGMDRD260FQI-23
iGMDRD255SB2250022
iGMDRD64Parbendazole7
iGMDRD60Quinoclamine2
iGMDRD23Gossypol4
iGMDRD356PNU-746543
iGMDRD451Serdemetan2
iGMDRD188Piperlongumine5
iGMDRD399Selumetinib3
iGMDRD506Fedratinib4
iGMDRD562Navitoclax6
iGMDRD560MK-22062
iGMDRD345Compound 10b [PMID: 11504634]2
iGMDRD79Gemcitabine4
iGMDRD486Tosedostat1
iGMDRD584VER 1550081
iGMDRD512nutlin 35
iGMDRD211(1S,3R)-RSL32
iGMDRD123Isoevodiamine3
iGMDRD435BI-25368
iGMDRD811Anthracycline2
iGMDRD57Chloropentafluorobenzene4
iGMDRD351GW843682X1
iGMDRD237ABT-7514
iGMDRD434BMS-5369245
iGMDRD137Indisulam3
iGMDRD505Pevonedistat4
iGMDRD300Tozasertib3
iGMDRD886Compound 1541A2
iGMDRD552AZD-17752
iGMDRD286Nsc 63283913
iGMDRD414MST-3122
iGMDRD329Merck607
iGMDRD366PI-1038

Gene in drug-gene network: Network Plot

Gene-drug targets distribution

Gene Structure: PDB

Models in TOP2A

​​​​